The standard treatment for ovarian, fallopian tube, and primary peritoneal (abdominal) cancer is a combination of commercially available chemotherapy drugs, cisplatin or carboplatin and paclitaxel, given intravenously or given directly in the peritoneal cavity.  Giving chemotherapy directly into the abdomen is called intraperitoneal chemotherapy (IP).  A special catheter is placed in the abdominal cavity. The IP chemotherapy drugs are delivered through this catheter.  Because ovarian, fallopian tube, and peritoneal primary cancer spread in the abdominal cavity, giving chemotherapy drugs directly into the abdominal cavity may result in more of the drug reaching the tumor cells. On this study the drugs to be administered into the abdominal cavity, cisplatin, carboplatin, and paclitaxel, are standard, non-experimental drugs used for the treatment of ovarian cancer and have been safely administered into the abdominal cavity in other patients with this type of cancer.  There have been documented survival advantages in ovarian cancer patients treated with IP chemotherapy.  But recently there have also been documented survival advantages in ovarian cancer patients treated with weekly intravenous (IV) paclitaxel. Controversy exists between the best treatment available for women with these cancers. This study will compare IV chemotherapy with two different IP treatment regimens to determine if there is a survival benefit. This study will also collect information on side effects and possible complications of IP administration. This study will ask patients with questionnaires how they feel during treatment to assess the risks and benefits of each treatment from the patient’s perspective. 

Another purpose of this study is to compare how cancer responds to one of three different chemotherapy regimens when given with a newer drug, bevacizumab.